Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 7, 2025

APC anti-human CD8

RRID:AB_2075388
Type: Antibody

Proper Citation

(BioLegend Cat# 344722, RRID:AB_2075388)

Antibody Information

URL: http://antibodyregistry.org/AB_2075388

Proper Citation: (BioLegend Cat# 344722, RRID:AB_2075388)

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-human CD8

Description: This monoclonal targets CD8

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone SK1

Antibody ID: AB_2075388

Vendor: BioLegend

Catalog Number: 344722

Alternative Catalog Numbers: 344721

Record Creation Time: 20231110T050708+0000

Record Last Update: 20241115T132357+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-human CD8.

No alerts have been found for APC anti-human CD8.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Aoki H, et al. (2024) CD8+ T cell memory induced by successive SARS-CoV-2 mRNA vaccinations is characterized by shifts in clonal dominance. Cell reports, 43(3), 113887.

Li Y, et al. (2024) SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency. Science translational medicine, 16(731), eadk1599.

Radziszewska A, et al. (2024) Type I interferon and mitochondrial dysfunction are associated with dysregulated cytotoxic CD8+ T cell responses in juvenile systemic lupus erythematosus. Clinical and experimental immunology.

Yin S, et al. (2024) Patient-derived tumor-like cell clusters for personalized chemo- and immunotherapies in non-small cell lung cancer. Cell stem cell, 31(5), 717.

Ma S, et al. (2024) Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity. Cancer cell.

Vallet N, et al. (2023) Circulating T cell profiles associate with enterotype signatures underlying hematological malignancy relapses. Cell host & microbe, 31(8), 1386.

Xu F, et al. (2023) Prostate cancer cell-derived exosomal IL-8 fosters immune evasion by disturbing glucolipid metabolism of CD8+ T cell. Cell reports, 42(11), 113424.

Cheng Y, et al. (2023) High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma. Cell reports. Medicine, 4(10), 101214.

Mudd PA, et al. (2022) SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell, 185(4), 603.

Chen W, et al. (2022) Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8+ T cell exhaustion and curtails anti-PD-1 efficacy. Cell reports, 41(7), 111647.

Li K, et al. (2022) Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Cancer cell, 40(11), 1374.

Oner A, et al. (2022) Transwell migration assay to interrogate human CAR-T cell chemotaxis. STAR protocols, 3(4), 101708.

Hu B, et al. (2022) IFN? Potentiates Anti-PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment. Cancer discovery, 12(7), 1718.

Reif T, et al. (2021) Contact-dependent inhibition of HIV-1 replication in ex vivo human tonsil cultures by polymorphonuclear neutrophils. Cell reports. Medicine, 2(6), 100317.

Kasper M, et al. (2021) Intraocular dendritic cells characterize HLA-B27-associated acute anterior uveitis. eLife, 10.

Loo Yau H, et al. (2021) Measuring the effect of drug treatments on primary human CD8+ T cell activation and cytolytic potential. STAR protocols, 2(2), 100549.

Clayton KL, et al. (2021) HIV-infected macrophages resist efficient NK cell-mediated killing while preserving inflammatory cytokine responses. Cell host & microbe, 29(3), 435.

Fierle JK, et al. (2021) Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1. Cell reports. Medicine, 2(8), 100362.

Hoseini SS, et al. (2021) T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia. Journal for immunotherapy of cancer, 9(5).

Lu Y, et al. (2020) Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced Immunity. Cell, 180(6), 1081.